Why a new name?
In 2023, the major liver societies (European, American and Latin American) adopted a new nomenclature. Non-alcoholic fatty liver disease (NAFLD) becomes MASLD, for Metabolic dysfunction-Associated Steatotic Liver Disease. Its inflammatory form, formerly called NASH, becomes MASH.
It is more than a new word: diagnosis now relies on positive criteria, not only on the absence of alcohol use.
What is MASLD?
MASLD means there is excess fat in the liver (steatosis) together with at least one cardiometabolic risk factor:
- overweight or a large waist circumference;
- high blood sugar or type 2 diabetes;
- high blood pressure;
- high triglycerides or low "good" cholesterol (HDL).
It is the most common liver disease, affecting nearly one adult in three worldwide. Usually silent, it can progress in some patients to fibrosis, cirrhosis and liver cancer.
What the 2024 European guidelines say
Published in 2024 in the Journal of Hepatology by EASL, EASD and EASO, they stress three points:
- look for the disease in people at risk: type 2 diabetes, obesity with another metabolic factor, abnormal liver tests or steatosis found on ultrasound;
- assess fibrosis step by step, without a biopsy in most cases: a score calculated from a simple blood test (FIB-4), then liver elastography if needed;
- change lifestyle first, and treat diabetes, blood pressure and cholesterol.
How to protect your liver
- lose weight if you are overweight: losing about 5% reduces liver fat, and losing 7 to 10% or more improves inflammation and fibrosis;
- follow a Mediterranean-style diet: vegetables, fruit, legumes, fish, olive oil, little added sugar and few sugary drinks (see our dietary advice);
- get regular physical activity, even moderate;
- avoid alcohol, which worsens liver damage.
Specific medicines are starting to be approved in some countries for forms with fibrosis. Whether they are appropriate is a specialist decision. To learn more about liver diseases, see our Hepatology page.